These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25857701)

  • 21. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya.
    Munywoki PK; Koech DC; Agoti CN; Lewa C; Cane PA; Medley GF; Nokes DJ
    J Infect Dis; 2014 Jun; 209(11):1685-92. PubMed ID: 24367040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating epidemiological and genetic data with different sampling intensities into a dynamic model of respiratory syncytial virus transmission.
    Kombe IK; Agoti CN; Munywoki PK; Baguelin M; Nokes DJ; Medley GF
    Sci Rep; 2021 Jan; 11(1):1463. PubMed ID: 33446831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
    Chu HY; Tielsch J; Katz J; Magaret AS; Khatry S; LeClerq SC; Shrestha L; Kuypers J; Steinhoff MC; Englund JA
    J Clin Virol; 2017 Oct; 95():90-95. PubMed ID: 28903080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
    Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
    Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
    Lee Mortensen G; Harrod-Lui K
    Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
    Zhu T; Zhang C; Yu L; Chen J; Qiu H; Lyu W; Huang S
    Virol Sin; 2015 Oct; 30(5):371-8. PubMed ID: 26511990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential impact of a maternal vaccine for RSV: A mathematical modelling study.
    Hogan AB; Campbell PT; Blyth CC; Lim FJ; Fathima P; Davis S; Moore HC; Glass K
    Vaccine; 2017 Oct; 35(45):6172-6179. PubMed ID: 28967522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.
    van Boven M; Teirlinck AC; Meijer A; Hooiveld M; van Dorp CH; Reeves RM; Campbell H; van der Hoek W;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S688-S694. PubMed ID: 32821916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?
    Saso A; Kampmann B
    Lancet Infect Dis; 2016 Aug; 16(8):e153-63. PubMed ID: 27317449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.
    Nyiro JU; Kombe IK; Sande CJ; Kipkoech J; Kiyuka PK; Onyango CO; Munywoki PK; Kinyanjui TM; Nokes DJ
    PLoS One; 2017; 12(5):e0177803. PubMed ID: 28531224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory syncytial virus infection and the need for immunization in Korea.
    Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
    Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
    Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
    BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.